Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG106 + Neoadjuvant Chemo in HER2- Breast Cancer
NCT05275777Phase 2Active, not recruiting
- Sponsor
- National University Hospital
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ADG106 in breast cancer and solid tumor (3 arms), sponsored by National University Hospital. Primary endpoints: Number of participant with treatment related toxicities, Histological response after neoadjuvant ADG106 + chemotherapy and 2 more. Started May 2022; status: active, not recruiting.
02
Drugs
ADG106
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05275777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275777.